Tamtam Try Tamtam free
Krka logo

Krka account plan

Generic pharmaceutical production and sales

At a glance

Krka is a Slovenian vertically integrated generic pharmaceutical group: 2025 revenue €2,041.0 million, 13,236 employees, sales in over 70 countries.

Krka, d. d., Novo mesto (founded 1954, listed on the Ljubljana Stock Exchange) is a vertically integrated generic pharmaceutical group that controls R&D, API and finished-product manufacturing, and marketing and sales through its own network. It sells prescription and non-prescription medicines, animal health products and health resort services to wholesalers, hospitals and pharmacies; over 100 million people use its products in over 70 countries, and markets outside Slovenia are 94% of sales. In 2025 revenue was €2,041.0 million (+7%), EBITDA €558.7 million (27.4% margin) and net profit €403.7 million (+13%). It had 13,236 employees at year-end 2025, 42% outside Slovenia, and has no non-current borrowings.

Business units

Strategic priorities

2026–2030 growth and margin targets
At least 5% average annual sales growth, an average EBITDA margin of at least 25% and at least 50% of net profit paid as dividends, with a top-5 generic position in all traditional markets.
Single-pill combinations
More than 200 combination medicines launched, over 30% of total sales; management credits product mix as the main driver of the margin gain.
New therapeutic areas
Entry into heart failure and obesity, plus complex formulations and peptide-based products; about 170 projects in development.
R&D at 10% of revenue
Allocate 10% of revenue to R&D, with more than 800 in-house experts; about 60% of R&D spend goes to new products and 40% to lifecycle management.
Supply reliability and global capacity
Treat supply reliability as a strategic asset and globalise capacity through joint ventures in India and China, with an average €150 million a year for capacity and infrastructure.
Digitalisation and automation
Accelerated digitalisation and automation, including artificial intelligence tools; an R&D digitalisation strategy for 2026–2030 was prepared.

Latest results

In January–September 2026 revenue rose 8% to €1,660.0 million, with 94% of sales outside Slovenia. Profitability grew faster: EBITDA rose 21% to €527.9 million (margin 31.8%), EBIT 24% to €455.5 million and net profit 13% to €364.2 million, as cost of goods sold stayed flat at €650.2 million. Region East Europe grew 14% to €606.7 million, led by the Russian Federation (+18%), while Region West Europe fell 2%. The 2026 estimate was raised to revenue of €2,179 million and net profit of €439 million, and the 2027 plan targets €2,308 million revenue and €474 million net profit.

Investments and deals

India joint venture with Laurus Labs
Krka holds 51% of Krka Pharma Private Limited in Hyderabad; completion is now targeted by the end of 2027, adding about 3 billion tablets a year of capacity.
Slovenian plant upgrades
Investments of €87.3 million in January–September 2026 (+31%): Notol and Notol 2 upgrades, a sterile solutions line extension, a high-bay warehouse at Ljutomer and veterinary capacity at Bršljin.
Capex plan
2026 capex is now around €115 million because permits took longer; €141 million is planned for 2027.
Share buybacks and dividends
Dividend of €9.1 per share, the 27th consecutive increase; €31 million of buybacks in 9M 2026 and a new 3-year buyback programme for cancellation.

Challenges and risks

Rouble exposure
Foreign exchange risk is the only risk rated High: the long rouble position cannot be hedged with suitable instruments, and it produced a €9.7 million loss in 9M 2026.
Price erosion and raw materials
Management names price erosion, rising raw material prices, exchange rates and lower demand as risks to the plan.
Weak West Europe
Region West Europe sales fell 2% in 9M 2026, with declines in Italy, Spain, France, Belgium and the Netherlands.
Supply chain and quality risks
Supply of APIs and finished products, quality management, IT disruption and workforce availability are rated moderate risks.

What leadership says

“We are not only growing but growing more profitably.”

David Bratož, Member of the Management Board · Krka Group 1–9 2026 results webcast, 13 November 2026

“Profitability remains a top priority. We don't chase sales at the cost of margins.”

David Bratož, Member of the Management Board · FY 2025 preliminary results webcast, 29 January 2026

“The Krka Group continues to be financially stable, is not dependent on debt financing, provides its shareholders with an attractive return, and maintains its independent path of development.”

Jože Colarič, President and CEO · Annual Report 2025, April 2026

Where a supplier can help

Manufacturing automation and packaging
Tied to the plant upgrades and digitalisation priority: robotic cells, packaging lines and automated warehouses are already being bought for Notol and Ljutomer.
Capacity build-out in India
Tied to the India joint venture: equipment, engineering and validation suppliers for a site adding about 3 billion tablets a year.
Supply chain and quality systems
Tied to the supply reliability priority and the supply and quality risks: planning, serialisation and quality-management tools across a multi-site network.
R&D and regulatory digitalisation
Tied to the R&D at 10% of revenue priority and the R&D digitalisation strategy: tools that speed development and the high volume of registration procedures.
Sales force effectiveness
Tied to the growth targets: Krka relies on more than 4,000 medical representatives, so CRM and field-force analytics support top-5 positions in its markets.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Krka?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Krka

What does Krka do?

Krka develops, manufactures and sells generic prescription and non-prescription medicines and animal health products, and runs health resorts in Slovenia. It controls the chain from R&D and API production to its own sales network.

What is Krka's revenue?

2025 revenue was €2,041.0 million (+7%), the first time above €2 billion, with net profit of €403.7 million. The 2026 estimate is €2,179 million.

How many employees does Krka have?

13,307 employees at 30 September 2026, 42% of them outside Slovenia.

What is Krka's strategy?

The 2026–2030 strategy targets at least 5% annual growth and an EBITDA margin of at least 25%, built on combination medicines, new areas such as heart failure and obesity, and capacity in India and China.

Who leads Krka?

Jože Colarič has been President and CEO since 2005; the Management Board also includes Dr Aleš Rotar, Dr Vinko Zupančič and David Bratož.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)